Quarterly ResultMay 5, 2026, 04:47 PM
Theriva Biologics Licenses SYN-020, Reports Reduced Q1 Loss
AI Summary
Theriva Biologics entered a license agreement with Rasayana Therapeutics for SYN-020, receiving an upfront payment of $300,000 and potential future milestone payments. The company reported a net loss of $2.044 million for Q1 2026, a significant reduction from $4.324 million in Q1 2025. Cash and cash equivalents increased to $14.431 million, partly due to $2.303 million from an "at-the-market" offering. Despite these positive developments, the company continues to face going concern uncertainties and is actively seeking additional financing to fund its clinical trials and operations into Q1 2027.
Key Highlights
- Entered license agreement with Rasayana Therapeutics for SYN-020, receiving $300,000 upfront payment.
- Eligible for up to $16 million in development milestones and $22 million in sales milestones from Rasayana.
- Reported a net loss of $2.044 million for Q1 2026, significantly down from $4.324 million in Q1 2025.
- License revenue for Q1 2026 was $300,000, compared to $0 in Q1 2025.
- Research and development expenses decreased to $355,000 in Q1 2026 from $2.968 million in Q1 2025.
- Cash and cash equivalents increased to $14.431 million as of March 31, 2026, from $13.056 million at Dec 31, 2025.
- Raised $2.303 million from an "at-the-market" offering in Q1 2026.
- Anticipates current cash will fund operations into the first quarter of 2027.
Price Impact
More from TOVX